'Quad Shot' Radiation Plus Immunotherapy Improves Local Control in Head, Neck Cancer

  • 📰 Medscape
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 55%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A palliative Quad Shot radiotherapy regimen alongside concurrent immunotherapy can improve local control in symptomatic patients with head and neck cancer but may not improve overall survival.

Treatment with palliative "Quad Shot" radiotherapy with concurrent immunotherapy appears safe and significantly improves local control in symptomatic patients with recurrent and metastaticLocal disease progression can reduce the quality of life for symptomatic patients with recurrent and metastatic head and neck cancer.

In this single-center study, the researchers analyzed 70 patients with symptomatic head and neck cancer who received at least three cycles of Quad Shot radiotherapy with or without concurrent immunotherapy within 4 weeks of radiation.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Upfront Low-Dose Radiation Improves Advanced SCLC OutcomesResearchers added low-dose radiation to standard first-line treatment for extensive-stage small cell lung cancer to extend treatment benefits.
Source: Medscape - 🏆 386. / 55 Read more »

Adding Low-Dose Radiation Improves Survival Outcomes in Small Cell Lung CancerA small, single-arm study presented at the 2024 European Lung Cancer Congress suggests that adding low-dose radiation to the standard first-line treatment for extensive-stage small cell lung cancer (SCLC) improves patients' median progression-free and overall survival. The study included 30 patients and showed a higher median progression-free survival of 8.3 months and extended median overall survival beyond the study follow-up period of 17.3 months. These findings are considered promising compared to the results of the 2019 CASPIAN trial.
Source: Medscape - 🏆 386. / 55 Read more »

Stacey Sager proudly completes 20th round of radiation in breast cancer fight'Cancer can take many things but it will never take my hope.' A warm and heartfelt congratulations to our own Stacey Sager for completing her 20th round of radiation.
Source: ABC7NY - 🏆 592. / 51 Read more »